Patents by Inventor Michael E. Stern

Michael E. Stern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Joint fat pad formulations, and methods of use thereof
    Patent number: 10869955
    Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
  • Therapeutic methods using cyclosporine components
    Patent number: 10736936
    Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 11, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Michael E. Stern, David Power
  • Cyclosporin analogs
    Patent number: 10065992
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: September 4, 2018
    Assignee: Allergan, Inc.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • JOINT FAT PAD FORMULATIONS, AND METHODS OF USE THEREOF
    Publication number: 20170368236
    Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
    Type: Application
    Filed: January 28, 2016
    Publication date: December 28, 2017
    Inventors: Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
  • Cyclosporin analogs
    Patent number: 9561259
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 7, 2017
    Assignee: Allergan, Inc.
    Inventors: Michael E. Garst, William Robert Carling, David Arthur Scowen, Michael E. Stern, Christopher S Schaumburg
  • CYCLOSPORIN ANALOGS
    Publication number: 20170029469
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Application
    Filed: October 11, 2016
    Publication date: February 2, 2017
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Therapeutic Methods Using Cyclosporine Components
    Publication number: 20170020954
    Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Michael E. Stern, David Power
  • Cyclosporin analogs
    Patent number: 9493511
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 15, 2016
    Assignee: Allergan, Inc.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Therapeutic methods using cyclosporine components
    Patent number: 9457060
    Abstract: Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ulcers, peptic ulcers, conditions affecting the uterus and appendicitis.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: October 4, 2016
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, David Power
  • Cyclosporin Analogs
    Publication number: 20160022765
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Application
    Filed: October 2, 2015
    Publication date: January 28, 2016
    Inventors: Michael E. Garst, William Robert Carling, David Arthur Scowen, Michael E. Stern, Christopher S. Schaumburg
  • Cyclosporin analogs
    Patent number: 9175042
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: November 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Michael E. Garst, William Carling, David Scowen, Michael E. Stern, Christopher S. Schaumburg
  • CYCLOSPORIN ANALOGS
    Publication number: 20150065433
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Application
    Filed: November 6, 2014
    Publication date: March 5, 2015
    Applicant: ALLERGAN, INC.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • KLK-13 antibody inhibitor for treating dry eye
    Patent number: 8821874
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: September 2, 2014
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
  • KLK-13 ANTIBODY INHIBITOR FOR TREATING DRY EYE
    Publication number: 20140017245
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Application
    Filed: July 22, 2013
    Publication date: January 16, 2014
    Applicant: Allergan, Inc.
    Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
  • CYCLOSPORIN DERIVATIVES FOR TREATING INFLAMMATORY DISEASES AND CONDITIONS
    Publication number: 20140005124
    Abstract: The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.
    Type: Application
    Filed: August 30, 2013
    Publication date: January 2, 2014
    Applicant: Allergan, Inc.
    Inventors: Michael E. Garst, Michael E. Stern
  • METHODS OF TREATING OCULAR AND OTHER DISEASES WITH SYN-134R POLYPEPTIDE
    Publication number: 20130323202
    Abstract: Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 5, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Larry A. Wheeler
  • Cyclosporin derivatives for treating inflammatory diseases and conditions
    Patent number: 8524671
    Abstract: The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: September 3, 2013
    Assignee: Allergan, Inc
    Inventors: Michael E. Garst, Michael E. Stern
  • KLK-13 antibody inhibitor for treating dry eye
    Patent number: 8491905
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: July 23, 2013
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
  • Methods of treating ocular and other diseases with Syn-134R polypeptide
    Patent number: 8491912
    Abstract: Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: July 23, 2013
    Assignee: Allergan, Inc.
    Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Larry A. Wheeler
  • KLK-13 ANTIBODY INHIBITOR FOR TREATING DRY EYE
    Publication number: 20120276106
    Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.
    Type: Application
    Filed: June 28, 2012
    Publication date: November 1, 2012
    Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao